Eleonora Allocati

TL;DR: In this paper, a number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models.

TL;DR: A European overview of (list) prices of originator adalimumab, before and after loss of exclusivity; to report changes in the reimbursement status of ad alimumab products; and discuss relevant policy measures.

TL;DR: In this paper, the authors assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of insulin analogue biosimilars to benefit all key stakeholders.

TL;DR: In this article, an extensive narrative review of published papers and contextualizing the findings to provide future guidance is presented. And the authors conclude that multiple measures will be needed to attain and retain universal healthcare.

TL;DR: In Bangladesh, prevalence rates of patients with diabetes are growing across countries, and Bangladesh is no exception as discussed by the authors. Associated costs are also increasing, driven by costs associated with the complications of d...